

## Vimta Labs Limited

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



VLL\SE\082\2023-24  
Date: 31.01.2024

Listing Centre  
B S E Limited  
P J Towers, Dalal Street  
Mumbai: 400001  
**Scrip Code No.524394**

Asst Vice President  
National Stock Exchange of India Limited  
"Exchange Plaza", Bandra  
Kurla Complex, Bandra (E)  
Mumbai – 400051  
**Trading Symbol: VIMTALABS**

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 31<sup>st</sup> December 2023.

Pursuant to Regulation 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find attached the press release in connection with announcement of unaudited Standalone and Consolidated Financial Results for the 3<sup>rd</sup> quarter ended 31<sup>st</sup> December 2023.

This is for your information and records.

Thanking you,

Yours faithfully,  
for VIMTA LABS LIMITED

Sujani Vasireddi  
Company Secretary

Attachments: as above.



## Vimta Labs Limited Reports Q3 & 9M FY24 Results

**Q3 FY24 Total Income at Rs. 826 Mn up 5.2% YoY,  
EBITDA margins at 27.5%; PAT margin at 12.3%**

Hyderabad, January 31, 2024: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and nine months ended December 31, 2023.

### Consolidated Financial Results – Q3 & 9M FY24:

Particulars (Rs. Mn)	Q3FY24	Q3FY23	YoY	9MFY24	9MFY23	YoY
Total Income	826	785	5.2%	2,421	2,391	1.2%
EBITDA (including other income)	227	226	0.7%	659	735	(10.4%)
EBITDA Margin	27.5%	28.8%		27.2%	30.7%	
PAT	101	102	(1.1%)	287	355	(19.2%)
PAT Margin	12.3%	13.0%		11.8%	14.8%	
Basic EPS	4.6	4.6		12.9	16.0	

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "Q3 witnessed strong sequential growth, primarily driven by a significant rebound in our Food business volumes and robust pre-clinical business. The E&E segment continued to show strong traction, while our other segments remained stable during the quarter.

Despite the slow-paced overall demand recovery, our engagement in several major projects bolsters my confidence of growing sustainably in the coming years."

### Key Results Highlights for the Q3 & 9M FY24 (Consolidated):

#### Q3FY24

- ✓ Total Income for Q3FY24 at Rs. 826 Mn, a growth of 5.2% YoY
- ✓ EBITDA for Q3FY24 at Rs. 227 Mn; EBITDA margin at 27.5%
- ✓ PAT at Rs. 101 Mn
- ✓ Basic EPS at Rs. 4.6

#### 9MFY24

- ✓ Total Income at Rs. 2,421 Mn
- ✓ EBITDA at Rs. 659 Mn; EBITDA margins at 27.2%
- ✓ PAT was at Rs. 287 Mn
- ✓ Basic EPS was Rs. 12.9
- ✓ Cash flow From Operations at Rs. 575 Mn for 9MFY24; 9MFY24 Capex at Rs. 628 Mn

**PRESS RELEASE**

For Immediate dissemination



- ✓ Cash and Cash equivalents at Rs. 325 Mn as of 31<sup>st</sup> December 2023
- ✓ Debt to Equity ratio 0.05x

**ABOUT VIMTA LABS LIMITED:**

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides clinical diagnostic services and environmental assessments and testing services.

**CAUTIONARY STATEMENT:**

*This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<b>Investor Relations at Vimta Labs</b> Narahai Naidu Dodda, CFO <a href="mailto:Narahai.Dodda@vimta.com">Narahai.Dodda@vimta.com</a>  <b>Ernst &amp; Young</b> Mr. Rahul Thakur <a href="mailto:Rahul.thakur@in.ey.com">Rahul.thakur@in.ey.com</a>  Mr. Advait Bhadekar <a href="mailto:Advait.bhadekar@in.ey.com">Advait.bhadekar@in.ey.com</a>	<b>Registered Office</b> Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: <a href="http://www.vimta.com">www.vimta.com</a>
--	--